Name: UMIN ID:
Unique ID issued by UMIN | UMIN000030892 |
---|---|
Receipt number | R000034363 |
Scientific Title | Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesothelioma |
Date of disclosure of the study information | 2018/01/19 |
Last modified on | 2023/02/10 14:09:20 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2018/01/19 14:23:53 | ||
2 | Update | 2018/02/16 13:05:41 | Recruitment status |
|
3 | Update | 2018/07/23 09:44:23 | Key exclusion criteria Key exclusion criteria |
|
4 | Update | 2018/07/23 09:46:28 | Key secondary outcomes Key secondary outcomes |
|
5 | Update | 2019/06/03 10:39:20 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Address Address Address Address Organization Organization Address Address Tel |
|
6 | Update | 2019/06/03 10:49:33 | Recruitment status Date of IRB Last follow-up date |
|
7 | Update | 2019/06/03 11:32:20 | Number of participants that the trial has enrolled |
|
8 | Update | 2019/06/25 10:44:50 | Key exclusion criteria |
|
9 | Update | 2019/10/29 13:15:29 | Last follow-up date |
|
10 | Update | 2019/10/29 13:18:08 | Last follow-up date |
|
11 | Update | 2020/10/21 14:22:15 | Last follow-up date |
|
12 | Update | 2023/02/10 14:09:20 | Recruitment status |